Skip to main content
Premium Trial:

Request an Annual Quote

MicroFluidic Systems Gets Rights to Lysis Technique from Lawrence Livermore

NEW YORK, Oct. 22--California start-up MicroFluidic Systems has struck a licensing deal for an ultrasonic cell lysis method from Lawrence Livermore National Laboratory, the company said yesterday.


The technique uses ultrasonic energy in a fluid-filled chamber to break open cells for DNA analysis. It can quickly lyse even spore-forming bacteria like anthrax, according to the company. This ability makes it potentially useful in developing systems for DNA-based pathogen detection, and MicroFluidic Systems plans to perfect the technique for pathogen sample processing.


MicroFluidic Systems was founded in 2001 by Cepheid alumni M. Allen Northrup, Farzad Pourahmadi, and Phil Belgrader. Belgrader previously conducted research on DNA analysis instrumentation at Lawrence Livermore, and is named in the patent for this lysis technique.


The company has technology development contracts with Roche Diagnostics and with the Defense Advanced Research Agency (DARPA).


For further information, see the company website.


The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.